The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment.
What to Expect from a Potential Trump Administration in 2025
As Donald Trump campaigns for a potential return to the presidency, speculation grows about what his administration might prioritize and how it would shape the
